Literature DB >> 32705544

Use of Multipotent Mesenchymal Stromal Cells, Fibrin, and Scaffolds in the Production of Clinical Grade Bone Tissue Engineering Products.

Joaquim Vives1,2,3, Luciano Rodríguez4, Maria Isabel Coca4, Laura Reales4, Raquel Cabrera-Pérez4,5, Lluís Martorell4,5.   

Abstract

Tissue engineering products (TEP) are a new type of medicines resulting from the combination of cells, scaffolds, and/or signalling factors, which can be used for the regeneration of damaged tissues thus opening new avenues for the treatment of complex conditions. However, such combination of biologically active elements, particularly living cells, poses an unprecedented challenge for their production under pharmaceutical standards.In the methods presented here, we formulated two types of TEP based on the use of multipotent mesenchymal stromal cells with osteogenic potential combined with osteoinductive and osteoconductive bony particles from tissue bank embedded in a fibrin hydrogel that, altogether, can induce the generation of new tissue while adapting to the diverse architecture of bony defects. In agreement with pharmaceutical quality and regulatory requirements, procedures presented herein can be performed in compliance with current good manufacturing practices and be readily implemented in straightforward facilities at hospitals and academic institutions.

Entities:  

Keywords:  Bone; Cell-based therapy; Fibrin glue; Good manufacturing practice; Multipotent mesenchymal stromal cells; Regenerative medicine; Scaffold; Tissue engineering product

Year:  2021        PMID: 32705544     DOI: 10.1007/7651_2020_280

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  11 in total

Review 1.  Mesenchymal Stromal Cells: Clinical Challenges and Therapeutic Opportunities.

Authors:  Jacques Galipeau; Luc Sensébé
Journal:  Cell Stem Cell       Date:  2018-06-01       Impact factor: 24.633

Review 2.  Quality compliance in the shift from cell transplantation to cell therapy in non-pharma environments.

Authors:  Joaquim Vives; Irene Oliver-Vila; Arnau Pla
Journal:  Cytotherapy       Date:  2015-03-10       Impact factor: 5.414

Review 3.  The Landscape of Cellular and Gene Therapy Products: Authorization, Discontinuations, and Cost.

Authors:  Vaishali Shukla; Enrique Seoane-Vazquez; Souhiela Fawaz; Lawrence Brown; Rosa Rodriguez-Monguio
Journal:  Hum Gene Ther Clin Dev       Date:  2019-07-16       Impact factor: 5.032

4.  A reproducible method for the isolation and expansion of ovine mesenchymal stromal cells from bone marrow for use in regenerative medicine preclinical studies.

Authors:  Marta Caminal; Roberto Vélez; Rosa Maria Rabanal; Daniel Vivas; Laura Batlle-Morera; Màrius Aguirre; Jordi Barquinero; Joan García; Joaquim Vives
Journal:  J Tissue Eng Regen Med       Date:  2016-11-18       Impact factor: 3.963

5.  Design and validation of a consistent and reproducible manufacture process for the production of clinical-grade bone marrow-derived multipotent mesenchymal stromal cells.

Authors:  Margarita Codinach; Margarita Blanco; Isabel Ortega; Mireia Lloret; Laura Reales; Maria Isabel Coca; Sílvia Torrents; Manel Doral; Irene Oliver-Vila; Miriam Requena-Montero; Joaquim Vives; Joan Garcia-López
Journal:  Cytotherapy       Date:  2016-07-14       Impact factor: 5.414

6.  Final results of a phase I-II trial using ex vivo expanded autologous Mesenchymal Stromal Cells for the treatment of osteoarthritis of the knee confirming safety and suggesting cartilage regeneration.

Authors:  Robert Soler; Lluis Orozco; Ana Munar; Marina Huguet; Ramon López; Joaquim Vives; Ruth Coll; Margarita Codinach; Joan Garcia-Lopez
Journal:  Knee       Date:  2016-01-11       Impact factor: 2.199

7.  Clinical translation of a mesenchymal stromal cell-based therapy developed in a large animal model and two case studies of the treatment of atrophic pseudoarthrosis.

Authors:  Salvi Prat; Santiago Gallardo-Villares; Marian Vives; Ana Carreño; Marta Caminal; Irene Oliver-Vila; Daniel Chaverri; Margarita Blanco; Margarita Codinach; Pere Huguet; José Ramírez; Javier A Pinto; Màrius Aguirre; Ruth Coll; Joan Garcia-López; Fernando Granell-Escobar; Joaquim Vives
Journal:  J Tissue Eng Regen Med       Date:  2017-06-01       Impact factor: 3.963

8.  Evaluation of a cell-banking strategy for the production of clinical grade mesenchymal stromal cells from Wharton's jelly.

Authors:  Irene Oliver-Vila; Maria Isabel Coca; Marta Grau-Vorster; Noèlia Pujals-Fonts; Marta Caminal; Alba Casamayor-Genescà; Isabel Ortega; Laura Reales; Arnau Pla; Margarita Blanco; Joan García; Joaquim Vives
Journal:  Cytotherapy       Date:  2015-11-06       Impact factor: 5.414

Review 9.  Safety of cell therapy with mesenchymal stromal cells (SafeCell): a systematic review and meta-analysis of clinical trials.

Authors:  Manoj M Lalu; Lauralyn McIntyre; Christina Pugliese; Dean Fergusson; Brent W Winston; John C Marshall; John Granton; Duncan J Stewart
Journal:  PLoS One       Date:  2012-10-25       Impact factor: 3.240

10.  Stability enhancement of clinical grade multipotent mesenchymal stromal cell-based products.

Authors:  Clémentine Mirabel; Eduard Puente-Massaguer; Anna Del Mazo-Barbara; Blanca Reyes; Philip Morton; Francesc Gòdia; Joaquim Vives
Journal:  J Transl Med       Date:  2018-10-24       Impact factor: 5.531

View more
  1 in total

1.  A pilot study of circulating levels of TGF-β1 and TGF-β2 as biomarkers of bone healing in patients with non-hypertrophic pseudoarthrosis of long bones.

Authors:  Daniel Chaverri; Daniel Vivas; Santiago Gallardo-Villares; Fernando Granell-Escobar; Javier A Pinto; Joaquim Vives
Journal:  Bone Rep       Date:  2021-12-09
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.